Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) FCF Margin (2019 - 2025)

C4 Therapeutics' FCF Margin history spans 7 years, with the latest figure at 206.31% for Q4 2025.

  • For Q4 2025, FCF Margin rose 13999.0% year-over-year to 206.31%; the TTM value through Dec 2025 reached 275.73%, down 9211.0%, while the annual FY2025 figure was 276.24%, 9263.0% down from the prior year.
  • FCF Margin reached 206.31% in Q4 2025 per CCCC's latest filing, up from 276.46% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 41.54% in Q2 2024 to a low of 1072.81% in Q4 2022.
  • Average FCF Margin over 5 years is 388.27%, with a median of 315.38% recorded in 2021.
  • Peak YoY movement for FCF Margin: plummeted -94495bps in 2022, then skyrocketed 67258bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 127.86% in 2021, then tumbled by -739bps to 1072.81% in 2022, then soared by 36bps to 689.24% in 2023, then soared by 50bps to 346.3% in 2024, then surged by 40bps to 206.31% in 2025.
  • Per Business Quant, the three most recent readings for CCCC's FCF Margin are 206.31% (Q4 2025), 276.46% (Q3 2025), and 186.55% (Q2 2025).